by Pete Celano | Jun 15, 2026 | Blog
Per the article from FirstWorld Pharma titled “Nudge increases prescriptions of medication for drinking”, published June 9, 2026– A “nudging” strategy in the emergency department (ED) may be a path for prescribing a medication that can blunt cravings...
by Pete Celano | Jun 7, 2026 | Blog
THE FEHV: The Foundation for the Study of Viral Hepatitis is a leading international non-profit organization in the field of hepatology , with top specialists in liver diseases and molecular biology. At our clinic in Madrid, we treat all types of liver diseases...
by Pete Celano | Jun 1, 2026 | Blog
We will miss Tony Villiotti’s peerless innovation in moving liver disease in America from very low awareness among patients, payers and providers, to its current state of surging enthusiasm, energy and engagement.
by Pete Celano | May 26, 2026 | Blog
This May 26, 2026 article cleverly titled “From Margin to Mainstream: Why Liver Health Should Sit at the Centre of the Global NCD Response” by Jeffrey Lazarus in Health Policy Watch is a call to (overdue) action.Jeffrey Lazarus is the Professor of Global...
by Pete Celano | May 23, 2026 | Blog
Big Gilead news: “FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)”. Gilead announced that the FDA has granted accelerated approval to Hepcludex...
